Navigation Links
Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
Date:9/2/2010

>  

STOCKHOLM, September 2, 2010 /PRNewswire/ --

- Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions

Three new analyses of subgroups from the SORT OUT III study presented at the European Society of Cardiology (ESC) meeting in Stockholm, Sweden, provide additional detail on longer-term follow-up subgroup safety and efficacy outcomes in the SORT OUT III trial in three high-risk subgroups (diabetes, acute coronary syndrome and multiple lesion). These important data add detail to those already published in the March 2010 issue of The Lancet on the clinical outcomes for the primary endpoint in the total population and in multiple subgroups at 9 months follow-up and on clinical outcomes at 18 month follow up of the randomized comparison of the CYPHER(R) Stent and the Endeavor(R) Stent.

The initial results of the SORT OUT III study were published in the Lancet and showed significantly reduced adverse events at 9 and 18 months for the CYPHER(R) Sirolimus-eluting Coronary Stent over Medtronic's Endeavor(R) Stent in an unselected group of 2,332 patients undergoing coronary intervention in real world clinical practice. The authors reported that subgroup analysis of the primary endpoint of 9-month Major Adverse Cardiac Events (MACE, defined as a composite of cardiac death, myocardial infarction [MI], or target vessel revascularization [TVR]) were also consistent across all subgroups.

The new data from ESC provide important additional information on longer-term outcomes at 18 months in three key groups of patients that are at higher risk of adverse events when undergoing coronary intervention, namely patients with diabetes, acute coronary syndromes, and treatment of multiple lesions. These data confirm that the significant reductions in major adverse events in these subgroups seen at 9 months
'/>"/>

SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010
2. Resverlogix Scientific Data Presented at EAS Congress
3. Very Small Embryonic-Like Stem Cell Mobilization Data Presented at International Society for Stem Cell Research Annual Meeting
4. Delcath Highlights Phase III Trial Results Presented at ASCO
5. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
6. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
7. Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting
8. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
9. Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
10. Zymes LLC, University of Windsor and National Research Council of Canada Collaborative Research Presented at the 2010 Experimental Biology Meeting in Anaheim, California
11. Gramene Announces Scholarships for Groups Underrepresented in Science to Learn How to Use Bioinformatics and Genomics Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... Fla. , Sept. 11, 2014 /PRNewswire/ ... anti-infective pharmaceuticals, announced today that the United ... a ,Notice of Allowance, for patent application ... Uses,.  The ,486 patent application relates to ... through gene-silencing and can be designed to ...
(Date:9/11/2014)... Entries are now being accepted for the annual ... colleagues within the healthcare industry select who wins. Now in ... best in healthcare creative campaigns. The awards are unique in ... and wellness industry. All entries are placed online, and healthcare ... each category. , “No one knows what it takes ...
(Date:9/11/2014)... September 11, 2014 Genera Energy ... innovation and supply chain advancements, recently introduced its newest ... BIN-SPEC delivers a consistent biomass product to a customer’s ... a lower cost. , “After producing and harvesting ... place to convert a field crop into a uniform ...
(Date:9/11/2014)... 11, 2014 Central Florida board-certified veterinary ... partnerships with several Brevard County animal hospitals to bring ... been working in the area since January 2006, credentialed ... 2008, and is happy to now offer his expertise ... Christiansen has used stem cell therapy with Vet-Stem, Inc. ...
Breaking Biology Technology:Lakewood-Amedex Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology 2Lakewood-Amedex Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology 3PM360 Now Accepting Entries for 2014 Pharma Choice Awards 2Genera Energy’s BIN-SPEC™ Reduces Biomass Feedstock Variability 2Genera Energy’s BIN-SPEC™ Reduces Biomass Feedstock Variability 3Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 2Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 3
... ON - Clean solutions to human energy demands are essential ... of energy at our disposal, we have yet to learn ... According to University of Toronto chemistry professor Greg Scholes, the ... in nature. "Solar fuel production often starts with the ...
... Citizens Bank today announced that it is providing $70 ... The Wistar Institute that includes a new seven-story 89,700-square-foot ... and Spruce streets in University City. The ... basic biomedical research, particularly cancer research and vaccine development ...
... first laser in 1960 scientists discovered that shining a beam ... specifically, it produced light of exactly twice the frequency of ... The green laser pointers in use today to illustrate ... beautiful emerald beam is no easy feat. The green light ...
Cached Biology Technology:Nature offers key lessons on harvesting solar power, says U of T chemistry professor 2Citizens Bank Provides $70 Million in Financing Toward $100 Million Expansion of The Wistar Institute 2Stanford engineers create nanoscale nonlinear light source 2Stanford engineers create nanoscale nonlinear light source 3Stanford engineers create nanoscale nonlinear light source 4
(Date:9/12/2014)... and condition of extraction of type I collagen fibrils, ... of their circular circular cross sections stay distributed in ... the most part of them. Jean Charvolin and Jean-Francois ... Paris-Sud University propose therefore that, once the growth of ... their lateral size be limited by internal physical stresses ...
(Date:9/12/2014)... to dealing with climate change: Advances in hydraulic ... unreachable oil and natural gas within humanity,s grasp. ... from "fracking," which requires blasting huge amounts of ... formations, are the subject of new research that ... survey covers not only greenhouse gas impacts but ...
(Date:9/12/2014)... and POINT ROBERTS, Washington , ... Investorideas.com ( http://www.investorideas.com ) a global news source covering leading ... and experts on the September 9 th launch of ... of Goode Intelligence, Janice Kephart , founder of the ... Pereira of NXT-ID, Inc, (NASDAQ: NXTD ) ...
Breaking Biology News(10 mins):Conjecture on the lateral growth of Type I collagen fibrils 2Stanford-led study assesses the environmental costs and benefits of fracking 2Stanford-led study assesses the environmental costs and benefits of fracking 3Stanford-led study assesses the environmental costs and benefits of fracking 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 2Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 3Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 5
... cryo-electron microscopes, researchers at Baylor College of Medicine unmasked the ... doing so, opened the door to a better understanding of ... In a report that appears in and on the cover ... Chiu, professor in the BCM department of biochemistry and molecular ...
... Low-grade uranium ore is nicknamed "yellowcake" for its color ... or "yellow monster." , The yellow monster surfaced on ... the 1940s and continued for the next several decades. ... among mine workers and worries about environmental contamination among ...
... at Virginia Tech, Colorado State University, and Duke ... to determine gene function on a genome-wide scale ... fungus causes black spot disease, leading to considerable ... canola, cabbage, and broccoli. , Genomic methods ...
Cached Biology News:Unraveling the viral mechanism 2Study may help slay 'Yellow Monster' 2Study may help slay 'Yellow Monster' 3New method enables gene disruption in destructive fungal pathogen 2
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
... Whole Genome Amplification Kit utilizes a ... of genomic DNA and conversion of ... library molecules flanked by universal priming ... amplification of the library molecules using ...
... ultra-pure recombinant thermostable DNA polymerase obtained by ... polymerase gene in E. coli, Concentration: 5U/ul, ... Thermo Fisher Scientific, the world leader in ... to make the world healthier, cleaner and ...
... Analysis of large numbers of samples may ... system which requires minimum operator attention. ... PowerStream software and interface CE 4900. The ... operates in Windows XP and Windows 98 and ...
Biology Products: